Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update

Authors Tsuji Y, Dobrev D

Received 6 February 2013

Accepted for publication 26 March 2013

Published 23 April 2013 Volume 2013:9 Pages 165—175

DOI https://doi.org/10.2147/VHRM.S43720

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Yukiomi Tsuji,1 Dobromir Dobrev1–3

1Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, 2Division of Experimental Cardiology, Medical Faculty Mannheim, Heidelberg University, Mannheim, 3Deutsches Zentrum für Herz-Kreislauf-Forshcung [German Center for Cardiovascular Research], partner site Heidelberg/Mannheim, Mannheim, Germany

Abstract: Intravenous vernakalant has recently been approved in Europe as an atrial-selective antiarrhythmic drug for the conversion of recent-onset atrial fibrillation (AF). It inhibits atrial-selective K+ currents (IK,ACh and IKur) and causes rate-dependent atrial-predominant Na+ channel block, with only a small inhibitory effect on the rapid delayed rectifier K+ current (IKr) in the ventricle. Due to its atrial-selective properties, vernakalant prolongs the effective refractory period of the atria with minimal effects on the ventricles, being associated with a low proarrhythmic risk for torsades de pointes arrhythmias. Five pivotal clinical trials consistently demonstrated that vernakalant rapidly terminates AF with stable maintenance of sinus rhythm for up to 24 hours. A head-to-head comparative trial showed that the 90-minute conversion rate of vernakalant was substantially higher than that of amiodarone. Initially, a longer-acting oral formulation of vernakalant was shown to be effective and safe in preventing AF recurrence after cardioversion in a Phase IIb study. However, the clinical studies testing oral vernakalant for maintenance of sinus rhythm after AF cardioversion were prematurely halted for undisclosed reasons. This review article provides an update on the safety and efficacy of intravenous vernakalant for the rapid cardioversion of AF.

Keywords: atrial fibrillation, antiarrhythmic drug, atrial-selective K+ currents, Na+ channel block, ventricles

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS

Vascular Health and Risk Management 2013, 9:273-282

Published Date: 29 May 2013

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E

Vascular Health and Risk Management 2013, 9:207-228

Published Date: 8 May 2013

Endoglin: a critical mediator of cardiovascular health

Kapur NK, Morine KJ, Letarte M

Vascular Health and Risk Management 2013, 9:195-206

Published Date: 6 May 2013

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU

Vascular Health and Risk Management 2013, 9:125-133

Published Date: 24 March 2013

Metabolic biomarkers for predicting cardiovascular disease

Montgomery JE, Brown JR

Vascular Health and Risk Management 2013, 9:37-45

Published Date: 29 January 2013

The potential benefit of stem cell therapy after stroke: an update

Banerjee S, Williamson DA, Habib N, Chataway J

Vascular Health and Risk Management 2012, 8:569-580

Published Date: 10 October 2012

The ClaudicatioNet concept: design of a national integrated care network providing active and healthy aging for patients with intermittent claudication

Lauret GJ, Gijsbers HJ, Hendriks EJ, Bartelink ML, de Bie RA, Teijink JA

Vascular Health and Risk Management 2012, 8:495-503

Published Date: 24 August 2012

Percutaneous coronary intervention of a single coronary artery arising from the right sinus of Valsalva

Mehmet Akif Cakar, Ersan Tatli, Bilhan Ozalp, et al

Vascular Health and Risk Management 2010, 6:1077-1078

Published Date: 25 November 2010

Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study

Laura J Gray, Jennifer R Tringham, Melanie J Davies, et al

Vascular Health and Risk Management 2010, 6:837-842

Published Date: 20 September 2010